Kelly M Chin1, Richard N Channick2, James A de Lemos3, Nick H Kim2, Fernando Torres3, Lewis J Rubin2. 1. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX. Electronic address: kelly.chin@utsouthwestern.edu. 2. Department of Internal Medicine, University of California, San Diego, CA. 3. Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX.
Abstract
BACKGROUND: Thrombocytopenia develops in some patients with advanced pulmonary arterial hypertension (PAH) while receiving IV epoprostenol therapy. In this study, we evaluate whether epoprostenol use, other PAH medication use, hemodynamics, or PAH etiology are associated with thrombocytopenia in PAH. METHODS: Platelet counts were evaluated in 47 PAH patients receiving IV epoprostenol, and in 44 patients with an inadequate response to initial therapy with oral agents in a cross-sectional study. Associations between thrombocytopenia (platelet count < 150,000/mL) and epoprostenol use, hemodynamics, PAH etiology, and use of other PAH medications were evaluated in univariable and multivariable analyses. RESULTS: PAH subtypes included idiopathic (69%), fenfluramine (18%), connective tissue disease (10%), and congenital heart disease (2%)-associated PAH. Thrombocytopenia was observed in 34% of patients treated with epoprostenol, compared with 15% of patients receiving oral therapy (odds ratio [OR], 2.9; p < 0.05), and the association between epoprostenol and thrombocytopenia remained significant after adjustment for differences in hemodynamics (OR, 5.0; p < 0.05). Right atrial pressure (OR, 1.12 per mm Hg; p < 0.05) and mixed venous oxygen saturation (Svo(2)) [OR, 0.92 per percentage; p < 0.05] were also associated with thrombocytopenia in univariable analyses; after logistic regression analysis, both the use of epoprostenol and Svo(2) were independently associated with thrombocytopenia. In a separate analysis including only patients with current or prior epoprostenol use, epoprostenol dose and right atrial pressure were inversely associated with platelet count. CONCLUSION: Epoprostenol use and severity of hemodynamic abnormalities are associated with thrombocytopenia in PAH, and these effects appear to be independent and additive.
BACKGROUND:Thrombocytopenia develops in some patients with advanced pulmonary arterial hypertension (PAH) while receiving IV epoprostenol therapy. In this study, we evaluate whether epoprostenol use, other PAH medication use, hemodynamics, or PAH etiology are associated with thrombocytopenia in PAH. METHODS: Platelet counts were evaluated in 47 PAH patients receiving IV epoprostenol, and in 44 patients with an inadequate response to initial therapy with oral agents in a cross-sectional study. Associations between thrombocytopenia (platelet count < 150,000/mL) and epoprostenol use, hemodynamics, PAH etiology, and use of other PAH medications were evaluated in univariable and multivariable analyses. RESULTS: PAH subtypes included idiopathic (69%), fenfluramine (18%), connective tissue disease (10%), and congenital heart disease (2%)-associated PAH. Thrombocytopenia was observed in 34% of patients treated with epoprostenol, compared with 15% of patients receiving oral therapy (odds ratio [OR], 2.9; p < 0.05), and the association between epoprostenol and thrombocytopenia remained significant after adjustment for differences in hemodynamics (OR, 5.0; p < 0.05). Right atrial pressure (OR, 1.12 per mm Hg; p < 0.05) and mixed venous oxygen saturation (Svo(2)) [OR, 0.92 per percentage; p < 0.05] were also associated with thrombocytopenia in univariable analyses; after logistic regression analysis, both the use of epoprostenol and Svo(2) were independently associated with thrombocytopenia. In a separate analysis including only patients with current or prior epoprostenol use, epoprostenol dose and right atrial pressure were inversely associated with platelet count. CONCLUSION:Epoprostenol use and severity of hemodynamic abnormalities are associated with thrombocytopenia in PAH, and these effects appear to be independent and additive.
Authors: Steven M Kawut; Emilia Bagiella; Daichi Shimbo; David J Lederer; Nadine Al-Naamani; Kari E Roberts; R Graham Barr; Wendy Post; Evelyn M Horn; Russell Tracy; Paul Hassoun; Reda Girgis Journal: Contemp Clin Trials Date: 2010-12-10 Impact factor: 2.226
Authors: Steven M Kawut; Emilia Bagiella; David J Lederer; Daichi Shimbo; Evelyn M Horn; Kari E Roberts; Nicholas S Hill; R Graham Barr; Erika B Rosenzweig; Wendy Post; Russell P Tracy; Harold I Palevsky; Paul M Hassoun; Reda E Girgis Journal: Circulation Date: 2011-05-18 Impact factor: 29.690
Authors: Kristina T Kudelko; Kari Nadeau; Ann N Leung; Juliana Liu; François Haddad; Roham T Zamanian; Vinicio De Jesus Perez Journal: J Heart Lung Transplant Date: 2010-06-08 Impact factor: 10.247